7,088 Shares in Merck & Co., Inc. $MRK Bought by Strategic Investment Advisors MI

Strategic Investment Advisors MI purchased a new stake in Merck & Co., Inc. (NYSE:MRK) during the 1st quarter, Holdings Channel reports. The institutional investor purchased 7,088 shares of the company’s stock, valued at approximately $853,000.

Other large investors have also recently added to or reduced their stakes in the company. D.A. Davidson & CO. grew its holdings in Merck & Co., Inc. by 4.4% in the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after purchasing an additional 24,576 shares during the period. Farther Finance Advisors LLC increased its stake in Merck & Co., Inc. by 48.9% in the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock valued at $10,296,000 after purchasing an additional 32,114 shares in the last quarter. Norris Perne & French LLP MI raised its holdings in shares of Merck & Co., Inc. by 12.8% during the fourth quarter. Norris Perne & French LLP MI now owns 252,162 shares of the company’s stock valued at $26,543,000 after purchasing an additional 28,635 shares during the period. Pinnbrook Capital Management LP raised its holdings in shares of Merck & Co., Inc. by 95.2% during the fourth quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock valued at $2,450,000 after purchasing an additional 11,355 shares during the period. Finally, Cibc World Market Inc. boosted its position in shares of Merck & Co., Inc. by 32.6% during the 4th quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock worth $137,022,000 after purchasing an additional 320,143 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Barclays raised its price target on Merck from $140 to $150 and maintained an “overweight” rating, implying meaningful potential upside from recent trading levels. Barclays raises Merck price target
• Positive Sentiment: Erste Group modestly increased its fiscal 2027 EPS forecast to $9.54 from $9.52, signaling slightly stronger expectations for Merck’s longer-term earnings power. Erste Group raises Merck EPS estimate
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend supports the stock’s income appeal and represents an annualized yield of approximately 2.7%. Merck announces fourth-quarter dividend
• Positive Sentiment: A Merck-Wellcome joint venture is preparing doses of an experimental Ebola vaccine for clinical trials, providing a potential public-health and pipeline opportunity, although it is not an immediate earnings driver. Merck and Wellcome Ebola vaccine partnership
• Neutral Sentiment: Analysts expect second-quarter revenue of about $16.33 billion and a loss of $0.26 per share, with acquisition-related costs, Keytruda performance, and Gardasil demand likely to determine whether results beat or miss expectations. Merck second-quarter earnings preview
• Neutral Sentiment: Valuation analysis finds Merck attractive on discounted cash flow and cash-flow measures but more fairly valued based on earnings, suggesting further gains will require continued fundamental execution. Merck valuation analysis
• Negative Sentiment: Near-term uncertainty ahead of earnings—including acquisition costs and ongoing Gardasil challenges—may be weighing on sentiment despite expected strength from Keytruda. Merck earnings metrics preview

Merck & Co., Inc. Stock Down 0.3%

Merck & Co., Inc. stock opened at $129.95 on Friday. Merck & Co., Inc. has a fifty-two week low of $77.53 and a fifty-two week high of $135.05. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm’s 50-day simple moving average is $123.02 and its 200 day simple moving average is $118.37. The stock has a market cap of $320.96 billion, a PE ratio of 36.61, a price-to-earnings-growth ratio of 5.17 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter last year, the business posted $2.22 EPS. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Research analysts predict that Merck & Co., Inc. will post 2.74 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Barclays boosted their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday. Bank of America lifted their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Wells Fargo & Company upped their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Finally, Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Thirteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $134.50.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.